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YEAR IN CARDIOLOGY SERIES YEAR IN CARDIOLOGY SERIES2207Year in Interventional CardiologySimon R. Dixon, Cindy L. Grines
Dixon and Grines review several of the major scientific works published in the field of
interventional cardiology in 2010, including late-breaking trials presented at the major
conferences. The papers reviewed and summarized include several addressing the efficacy of
percutaneous valve therapies, several comparisons of different stent platforms, and a section on
relevant pharmacotherapies.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY2221Similar Outcomes With ZES or EES in Complex PCI PatientsGiulio G. Stefanini, Patrick W. Serruys, Sigmund Silber, Ahmed A. Khattab, Robert J. van Geuns,
Gert Richardt, Pawel E. Buszman, Henning Kelbæk, Adrianus J. van Boven, Sjoerd H. Hofma, Axel Linke,
Volker Klauss, William Wijns, Carlos Macaya, Philippe Garot, Carlo Di Mario, Ganesh Manoharan,
Ran Kornowski, Thomas Ischinger, Antonio L. Bartorelli, Pierre Gobbens, Stephan Windecker
Stefanini and colleagues present a pre-specified subgroup analysis of the impact of lesion or
patient complexity in the RESOLUTE All Comers trial (A Randomized Comparison of a
Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary
Intervention), in which subjects were randomized to zotarolimus-eluting stents (ZES) or
everolimus-eluting stents (EES). Two-thirds of the patients were classified as complex based
on factors such as acute myocardial infarction, chronic total occlusion, long stent length, or
renal insufficiency. Event rates were higher among complex patients but did not differ
between ZES and EES. The newer-generation ZES and EES appear to be similarly safe and
effective regardless of lesion or patient complexity.(continued on page A-23)
MAY 31, 2011 (continued) A-23pHEART FAILURE2233Diuretic Therapy May Improve Renal Tubular Function by Decreasing CongestionKevin Damman, Marie J. Ng Kam Chuen, Robert J. MacFadyen, Gregory Y. H. Lip, David Gaze,
Paul O. Collinson, Hans L. Hillege, Wim van Oeveren, Adriaan A. Voors, Dirk J. van Veldhuisen
Damman and colleagues studied whether volume overload hinders renal function through
elevation in central venous pressure. Thirty patients with chronic systolic heart failure in a
presumed euvolemic state and on standard oral furosemide therapy (40 to 80 mg) were
studied at baseline, after withholding diuretics for 3 days, and then after diuretic reinitiation.
Serum creatinine, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP),
urinary kidney injury molecule (KIM)-1, urinary N-acetyl-beta-D-glucosaminidase (NAG), as
well as urinary and serum neutrophil gelatinase associated lipocalin (NGAL) were determined
at various time points. Diuretic withdrawal resulted in increases in ANP and BNP, along
with urinary KIM-1 and NAG. Serum creatinine and serum and urinary NGAL did not
change significantly. These results suggest that diuretic therapy may favorably affect renal and
tubular function by decreasing renal congestion.Editorial Comment: Stephen S. Gottlieb, p. 2242HEART RHYTHM DISORDERS2244Flecainide Appears to Be Safe and Effective for CPVTChristian van der Werf, Prince J. Kannankeril, Frederic Sacher, Andrew D. Krahn, Sami Viskin,
Antoine Leenhardt, Wataru Shimizu, Naokata Sumitomo, Frank A. Fish, Zahurul A. Bhuiyan,
Albert R. Willems, Maurits J. van der Veen, Hiroshi Watanabe, Julien Laborderie, Michel Haïssaguerre,
Björn C. Knollmann, Arthur A. M. Wilde
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by genetic
mutations that cause calcium to be prematurely and excessively released from the sarcoplasmic
reticulum with catecholaminergic stimulation. van der Werf and colleagues reviewed the
efficacy and safety of flecainide in patients with genotype-positive CPVT. A total of 76% of
patients had either a partial or complete suppression of exercise-induced ventricular
arrhythmias by flecainide. Only 1 patient had significant breakthrough, and may not have
been compliant with flecainide at the time. Flecainide, which inhibits RyR2 channels and
prevents arrhythmogenic Ca2 waves, reduced exercise-induced ventricular arrhythmias in
atients with CPVT uncontrolled by conventional drug therapy.(continued on page A-24)
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EHEART RHYTHM DISORDERS2255Distinguishing LVOT From RVOT Origin With the V Transition Ratio2
Brian P. Betensky, Robert E. Park, Francis E. Marchlinski, Matthew D. Hutchinson, Fermin C. Garcia,
Sanjay Dixit, David J. Callans, Joshua M. Cooper, Rupa Bala, David Lin, Michael P. Riley,
Edward P. Gerstenfeld
Betensky and colleagues sought to develop electrocardiographic criteria for distinguishing left
ventricular outflow tract (LVOT) from right ventricular outflow tract (RVOT) origin in
patients with idiopathic outflow tract ventricular tachycardia (VT) and lead V3 R/S transition.
Sinus and VT QRS morphologies were measured in patients who had undergone successful
ablation. V2 and V3 transition ratios were calculated by computing the % R-wave during VT
(R/RS) divided by the % R-wave in sinus rhythm (R/RS). The V2 transition ratio was
significantly greater for LVOT premature ventricular contractions (PVCs) compared with
RVOT PVCs and was the only independent predictor of LVOT origin. A V2 transition ratio
0.60 predicted an LVOT origin with 91% accuracy. The V2 transition ratio can help to
identify the site of OT VT.IMAGING AND BIOMARKERS
2263Echocardiographic Tissue Velocity and Strain Imaging May Identify
Early Myocardial Damage From Adjuvant Trastuzumab TherapyNazanin Fallah-Rad, Jonathan R. Walker, Anthony Wassef, Matthew Lytwyn, Sheena Bohonis,
Tielan Fang, Ganhong Tian, Iain D. C. Kirkpatrick, Pawan K. Singal, Marianne Krahn, Debjani Grenier,
Davinder S. Jassal
Trastuzumab is associated with a 5% to 10% risk of cardiac dysfunction when used as
adjuvant therapy for the treatment of human epidermal growth factor receptor II-positive
breast cancer. Fallah-Rad and colleagues studied whether serial examinations could identify
patients likely to develop left ventricular dysfunction (LVD) prior to a deterioration in their
ejection fraction. Troponin T, C-reactive protein, and brain natriuretic peptide were not
useful, but there was a significant difference in the lateral S= at 3 months between the group
hat developed LVD and those that did not after 6 to 12 months of therapy. Tissue velocity
maging appears to be able to detect pre-clinical changes in left ventricular systolic function in
atients receiving trastuzumab as adjuvant therapy.
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aPRE-CLINICAL RESEARCH2273Caveloin-3 Microdomains Stimulate Natriuretic Peptide Expression and SignalingYousuke T. Horikawa, Mathivadhani Panneerselvam, Yoshitaka Kawaraguchi, Yasuo M. Tsutsumi,
Sameh S. Ali, Ravi C. Balijepalli, Fiona Murray, Brian P. Head, Ingrid R. Niesman, Timo Rieg,
Volker Vallon, Paul A. Insel, Hemal H. Patel, David M. Roth
Caveolae, microdomains in the plasma membrane, contain caveolin-3 (Cav-3) proteins and
natriuretic peptide receptors. Horikawa and colleagues generated transgenic mice with cardiac
myocyte-specific overexpression of caveolin-3 (Cav-3 OE) and then subjected them to
transverse aortic constriction. Cav-3 OE mice had increased survival, reduced cardiac
hypertrophy, and better cardiac function compared with control mice. Messenger ribonucleic
acid for atrial natriuretic peptide and brain natriuretic peptide was significantly increased in
Cav-3 OE mice. These results imply that stimulating Cav-3 may be a novel strategy to
exploit the therapeutic benefits of natriuretic peptides in cardiac hypertrophy and heart failure.EXPEDITED PUBLICATION EXPEDITED PUBLICATION2284Heritability and Clinical Predictors of Early Repolarization Pattern on ECGPeter A. Noseworthy, Jani T. Tikkanen, Kimmo Porthan, Lasse Oikarinen, Arto Pietila, Kennet Harald,
Gina M. Peloso, Faisal M. Merchant, Antti Jula, Heikki Väänänen, Shih-Jen Hwang,
Christopher J. O’Donnell, Veikko Salomaa, Christopher Newton-Cheh, Heikki V. Huikuri
Noseworthy and colleagues reviewed electrocardiograms (ECGs) from almost 10,000 subjects
to determine the incidence of the early repolarization pattern (ERP) and to determine if there
was evidence of a genetic basis for this pattern. ERP was defined as J-point elevation 0.1 mV
n 2 leads in either the inferior or lateral leads. ERP was present in 4.5% of subjects. Male
ex, younger age, lower systolic blood pressure, higher Sokolow-Lyon index, and lower
ornell voltage were independently associated with the presence of ERP. Siblings of
ndividuals with ERP were 2.2 times more likely to have ERP suggesting a heritable basis
nd thus further assessment of the genetic determinants of ERP appears warranted.
